DOW
loading...
NASDAQ
loading...
S&P
loading...




Action Alerts PLUS
RealMoney Silver
Market Movers
Stocks Under $10
Options Alerts
Breakout Stocks
View All


Now, enjoy the good life every day!

RSSRSS FEEDS
PODPODCASTS


RealMoney.com: Biotech
Print This Story

Unusual Trades In Cypress Bioscience

By Jon "DRJ" Najarian
RealMoney Contributor

12/24/2008 9:10 AM EST
Click here for more stories by Jon "DRJ" Najarian
 
Try Jim Cramer's Action Alerts PLUS
CLICK HERE NOW

 
Cypress Bioscience (CYPB - commentary - Cramer's Take) saw unusual trading yesterday, both in options and the stock itself.

CYPB's volume was heavier than normal, with more than 636,500 shares changing hands versus a daily average of about 572,000 during a slow holiday week for the rest of the market.

At the same time, nearly 8,000 puts traded at the January 5 strike--which makes me suspect that this might be a buy-stock/buy-put situation, otherwise known as a "synthetic call."

Two big blocks traded, one of 1,683 contracts and another of 4,703, at $0.63 and $0.75 respectively while the stock was up on the day, according to OptionMonster's systems, which track unusual options activity. (Hmm, buying puts and the stock rallies...) Also, volatility is exploding in CYPB, as median volatility was 75 but rose beyond 220 in the last few days.

The stock spiked late Monday and yesterday after the company reported positive results for an experimental drug to treat fibromyalgia. CYPB, which was trading near $5 earlier this month, closed yesterday at $6.44.






 RELATED STORIES

Biotech
Biotech Mailbag: Bad CEOs Offer Lessons
12/19/2008 7:01 AM EST
Senior Columnist Adam Feuerstein's selection of Kelly Martin as the worst biotech CEO for 2008 highlights the need for investors to scrutinize management teams before plunging into an investment.

Biotech
Novartis MS Drug Reduces Relapses
12/12/2008 7:07 AM EST
A study showed the company's experimental daily pill for multiple sclerosis was more effective than a currently approved injectable drug from Biogen Idec.

Biotech
Biotech Mailbag: NeurogesX Patchy at Best
12/5/2008 7:00 AM EST
It's not clear how this tiny biotech's pain patch can compete with a host of rivals, large and small.




Brokerage Partners



Write us!
Order reprints of TSC articles.

TheStreet Premium Services
Jim Cramer
Jim Cramer's Action Alerts PLUS
Now any level of investor can trade right alongside a Wall Street pro — and enjoy 24/7 access to his portfolio! Learn More
Doug Kass
RealMoney Silver
The genius of Doug Kass + 5 Premium Services = an unrivaled group of expert fundamental analysts, technical analysts, and Wall Street observers. Learn More
Don Dion
NEW! Don Dion's ETF Action
A concise two-step strategy for learning and trading in this increasingly lucrative area of investing. For all levels of investors! Learn More
David Peltier
Stocks Under $10
David Peltier is ready to help you find affordable stocks under $10. Because they're so inexpensive, the payout could be enormous! Learn More
Bryan Ashenberg
Breakout Stocks
Bryan Ashenberg combines sophisticated screening software with eagle-eye analysis to find small and mid-caps ready to break out! Learn More

Investor Relations | Privacy Policy | Terms of Use | Conflicts Policy | Corrections | Internet Index | Advertise | FAQ
Site Map | Who's Who | Reader Feedback | Employment | Contact Us
RSSSubscribe to our RSS Feed
© 1996- TheStreet.com, Inc. All rights reserved.
TheStreet.com's enterprise databases running Oracle are professionally monitored and managed by Pythian Remote DBA.